Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 02, 2023	Jul. 03, 2022	Jul. 02, 2023	Jul. 03, 2022
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]			$ 1,204
Provision/(credit)	[2]	$ 138	$ 147	94	$ 191
Utilization and other	[3]			(584)
Balance, ending	[4]	714		714
Other Current Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning				991
Balance, ending		556		556
Other Noncurrent Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning				213
Balance, ending		158		158
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]			1,196
Provision/(credit)				61
Utilization and other	[3]			(556)
Balance, ending	[4]	700		700
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]			0
Provision/(credit)				4
Utilization and other	[3]			(4)
Balance, ending	[4]	0		0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]			8
Provision/(credit)				29
Utilization and other	[3]			(23)
Balance, ending	[4]	$ 14		$ 14

[1] Included in Other current liabilities ($991 million) and Other noncurrent liabilities ($213 million).

[2] Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $4 million and credits of $23 million for the three and six months ended July 2, 2023, respectively, and charges of $50 million and $46 million for the three and six months ended July 3, 2022, respectively.

[3] Other activity includes adjustments for foreign currency translation that are not material.

[4] Included in Other current liabilities ($556 million) and Other noncurrent liabilities ($158 million).